Abstract
The treatment of muscle invasive bladder cancer (MIBC) is complex. This review describes the available therapies for invasive urothelial carcinoma. Neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) and lymph node dissection has been considered the slandered treatment for MIBC. Many patients those are unfit for surgery or cisplatin ineligible, bladder sparing strategies are considered in highly selected patients. Even though there are no level I data, the treatment outcomes for highly select patients given bladder sparing therapy appear promising, with many patients retaining a functional bladder. So it can be concluded that treatment of MIBC is a multidisciplinary collaborative program of surgery, radiation and medical oncology. Bangladesh Journal of Urology, Vol. 23, No. 2, July 2020 p.205-209
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
